Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Glioblastoma × Tetanus Toxoid × Clear all

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Multiple Myeloma 2 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms, Germ Cell and Embryonal 1 Lymphoma 1 Lipodystrophy, Congenital Generalized 1 Leukemia 1 Glioblastoma 1

Interventions

Temozolomide 49 Radiotherapy 22 Bevacizumab 22 Radiation 10 Carmustine 6 Radiosurgery 5 Magnetic Resonance Spectroscopy 5 Lomustine 5 Irinotecan 5 Radiotherapy, Intensity-Modulated 4 Nivolumab 4 Erlotinib Hydrochloride 4 Cilengitide 4 Aminolevulinic Acid 4 vocimagene amiretrorepvec 3 vitespin 3 sargramostim 3 poly ICLC 3 pembrolizumab 3 fluoromisonidazole 3 carmustine, poliferprosan 20 drug combination 3 TPI-287 3 O(6)-benzylguanine 3 Ipilimumab 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Flucytosine 3 Dynamic Contrast Enhanced Magnetic Resonance Imaging 3 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3 spartalizumab 2 selinexor 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02864368 2022-06-09

PERFORMANCE

Duke University

Phase 1 Terminated

27 enrolled 13 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡